Resonance Health Ltd ( (AU:RHT) ) just unveiled an announcement.
Resonance Health Ltd reported record financial performance for the half-year ending December 31, 2024, with customer receipts reaching $8.3 million, a 160% increase from the previous year. The company secured significant contracts in its CRO Services division, including a $13.8 million clinical trial contract, contributing to a total of $20.1 million in contract wins since August 2023. This growth reflects the company’s successful scaling of operations across its business units, positioning it strongly in the market.
More about Resonance Health Ltd
Resonance Health Ltd is a company operating in the medical technology industry, focusing on software-medical-device image-analysis, clinical trial investigator sites, and clinical trial management services. The company is known for its innovative solutions in medical imaging and clinical trials, catering to the needs of the healthcare and pharmaceutical sectors.
YTD Price Performance: 16.00%
Average Trading Volume: 247,167
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$26.66M
Learn more about RHT stock on TipRanks’ Stock Analysis page.